Watch ARCT. Know when insiders buy.
One email the day a filing lands. Free.
ARCT
Arcturus Therapeutics Holdings Inc.
11.11
+0.13 +1.18%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
68
PASS · shorts 68
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $315.8MP/E —DIV YIELD —FCF YIELD -23.06%REV TTM $29.4M −76.0%NET INCOME −$93.3MNET CASH $178.2M52W 5.53 – 23.16SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $3M | −89.5% | — | −$25.5M | −$23.8M | — | -0.84 | −$19.9M | $0 | −$19.9M | Aug 6 |
| Q1 2026 · Mar 31 | $2.1M | −93.0% | — | −$28.9M | −$27M | — | -0.95 | −$19.4M | $0 | −$19.4M | Aug 6 |
| Q4 2025 · Dec 31derived | $7.2M | −68.4% | — | −$31.3M | −$29.1M | — | -1.05 | −$16.2M | −$88K | −$16.1M | Mar 3 |
| Q3 2025 · Sep 30 | $17.2M | −58.8% | — | −$16.5M | −$13.4M | — | -0.49 | −$17.2M | $181K | −$17.3M | Nov 12 |
| Q2 2025 · Jun 30 | $28.3M | −43.2% | — | −$11.6M | −$9.2M | — | -0.34 | −$5.8M | $0 | −$5.8M | Aug 6 |
| Q1 2025 · Mar 31 | $29.4M | −22.7% | — | −$16.8M | −$14.1M | — | -0.52 | −$35.1M | $137K | −$35.3M | Aug 6 |
| Q4 2024 · Dec 31derived | $22.8M | −26.2% | — | −$33.4M | −$30M | — | -1.11 | −$284K | $0 | −$284K | Mar 3 |
| Q3 2024 · Sep 30 | $41.7M | −7.7% | — | −$10.7M | −$6.9M | — | -0.26 | −$23.8M | $80K | −$23.8M | Nov 12 |
| Q2 2024 · Jun 30 | $49.9M | — | — | −$21.1M | −$17.2M | — | -0.64 | −$30.1M | $328K | −$30.5M | Nov 12 |
| Q1 2024 · Mar 31 | $38M | — | — | −$30.4M | −$26.8M | — | -1.00 | −$5.6M | $240K | −$5.8M | Nov 12 |
| Q4 2023 · Dec 31derived | $30.9M | — | — | −$18.3M | −$11.7M | — | -0.44 | −$629K | $875K | −$1.5M | Mar 3 |
| Q3 2023 · Sep 30 | $45.1M | — | — | −$19.3M | −$16.2M | — | -0.61 | −$32.4M | $981K | −$33.4M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $82M | — | −$76.3M | −$65.8M | -80.2% | -2.40 | −$74.3M | $230K | −$74.5M | — | — |
| FY2024 · to Dec 31 | $152.3M | — | −$95.7M | −$80.9M | -53.1% | -3.00 | −$59.7M | $648K | −$60.4M | — | — |
| FY2023 · to Dec 31 | $166.8M | — | −$78.2M | −$29.7M | -17.8% | -1.12 | −$18.1M | $2.9M | −$21M | — | — |
| FY2022 · to Dec 31 | $206M | — | $12.2M | $9.3M | 4.5% | 0.35 | $32M | $7.7M | $24.3M | — | — |
| FY2021 · to Dec 31 | $12.4M | — | −$202.9M | −$203.7M | -1648.0% | -7.74 | −$135M | $3.4M | −$138.4M | — | — |
| FY2020 · to Dec 31 | $9.5M | — | −$71.5M | −$72.1M | -756.3% | -3.55 | −$42.9M | $1.7M | −$44.6M | — | — |
Every number comes from Arcturus Therapeutics Holdings Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.